CliffBio
small molecule

GLYCOPYRROLATE

GLYCOPYRROLATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameGLYCOPYRROLATE
Active ingredientGLYCOPYRROLATE
Strength0.6MG/3ML (0.2MG/ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, INTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.